

Treatments Partially Commissioned by other Commissioners. Exceptional Funding Request

Treatments are not commissioned by BNSSG ICB where;

- 1. policies have been developed by other Commissioners partially commissioning a care pathway, and
- 2. such polices place an expectation on the ICB to partially or wholly fund connected treatments, and
- 3. these treatments have not been properly considered and commissioned by the ICB in line with normal commissioning processes.

Bristol North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB) is responsible for making the best use of the NHS funds allocated to us to meet the health needs of our local population. The demand for services is greater than the resources available and therefore we have to prioritise the use of funds carefully. Our approach is to prioritise commissioning treatments, operations or drugs that are most effective in meeting the health needs of the population. All operations carry significant risks and where symptoms are mild or moderate it is likely that the risks outweigh the benefits. Not all conditions progress and when symptoms can be managed conservatively, that is the safest option.





Treatments Partially Commissioned by other Commissioners – Plain Language Summary

BNSSG ICB does not automatically agree to support funding solely based on funding approval being granted by another Commissioner. Local commissioning policies should be applied. Outside of these recommendations, a request for funding needs to be considered on an Individual basis by the Exceptional Funding Request Panel.

This policy has been developed with the aid of the following:

- Ash. (2016). ash.org.uk. Retrieved September 24th, 2018, from www.ash.org.uk: www.ash.org.uk/briefings England, N. (2013/2014). NHS England. Retrieved December 1st, 2018, from www.england.nhs.uk: https://www.england.nhs.uk/wpcontent/uploads/2013/10/int-gend-proto.pdf
- 2. Thelwall, S. P. (2015). Impact of obesity on the risk of wound infection following surgery: results from a nationwide prospective multicentre cohort study in England. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, , vol. 21, no. 11, p. 1008.e1.

Due regard

In carrying out their functions, the Bristol, North Somerset and South Gloucestershire Clinical Policy Review Group (CPRG) are committed to having due regard to the Public Sector Equality Duty (PSED). This applies to all the activities for which the ICB is responsible, including policy development and review.





Bristol, North Somerset and South Gloucestershire

Integrated Care Board

Document Control

Document Title	Treatments Partially Commissioned by other Commissioners
Author(s) job title(s):	Commissioning Policy Development Manager, BNSSG ICB Clinical Lead for Policy Development
Document version:	2223.01.01
Supersedes:	1819.02.02
Discussed at Commissioning Policy Review Group (CPRG):	25 th April 2023
Approval Route (see <u>Governance</u>):	Level – 1
Approval Date	25 th April 2023
Date of Adoption:	1 st August 2023
Publication/issue date:	1 st August 2023
Review due date:	Earliest of either NICE publication or three years from approval.

Governance

Commissioning policies are assessed for their likely level of impact on BNSSG ICB and the population for which it is responsible. This determines the appropriate level of sign off. The below described the approval route for each score category.

Policy Category	Approval By
Level 1	Commissioning Policy Review Group.
Level 2	Chief Medical Officer, or Chief Nursing Officer,
	or System Executive Group Chair
Level 3	ICB Board

OPCS Procedure codes

N/A





Support

If you would like further copies of this policy or need it in another format, such as Braille or another language, please contact the Customer Services Team on: **0117 900 2655** or **0800 073 0907** or email them on <u>BNSSG.customerservice@nhs.net</u>.

